The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Autologous blood injection for plantar fasciitis.
Plantar fasciitis occurs when the connective tissue between the heel and the middle of the foot deteriorates. This usually happens because of overuse or injury, and it causes foot pain. In autologous blood injection, blood is taken from the patient and injected into the area around the affected tissue. Sometimes the blood is separated into red blood cells and platelets (cell fragments that produce substances called growth factors) before injecting the sample containing mainly platelets. The aim is to supply the connective tissue with growth factors that promote the healing process.
T57.8 Other specified other operations on fascia
Y39.8 Other specified injection of other substance into organ NOC
Z90.5 Foot NEC
X36.8 Other specified blood withdrawal
Y53.2 Approach to organ under ultrasonic control is assigned following T57.8 when performed under ultrasonic guidance.
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Providers should ensure that governance structures are in place to review, authorise and monitor the introduction of new devices and procedures.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.